The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study
Open accessAbstract
Non-alcoholic fatty liver disease (NAFLD) is usually associated with insulin resistance, central obesity, reduced glucose tolerance, type 2 diabetes mellitus and hypertriacylglycerolaemia. The beneficial effects of resveratrol on metabolic disorders have been shown previously. The aim of this study was to evaluate the effects of resveratrol supplementation on cardiovascular risk factors in patients with NAFLD. In this randomised double-blinded placebo-controlled clinical trial, fifty NAFLD patients were supplemented with either a 500-mg resveratrol capsule or a placebo capsule for 12 weeks. Both groups were advised to follow an energy-balanced diet and physical activity recommendations. resveratrol supplementation reduced alanine aminotransferase (ALT) and hepatic steatosis significantly more than placebo (P0·05). There were no significant changes in blood pressure, insulin resistance markers and TAG in either group (P>0·05). Our data have shown that 12-week supplementation of 500 mg resveratrol does not have any beneficial effect on anthropometric measurements, insulin resistance markers, lipid profile and blood pressure; however, it reduced ALT and hepatic steatosis in patients with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Given that chronic hyperinsulinemia can stimulate an excessive production of androgens in PCOS women, the antiandrogenic effects of resveratrol are probably indirect and driven by the reduction of IR in these patients [141,142,143,144], in contrast to pharmacologic intervention with metformin [145,146].”
From Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases (2020) · cites this paper as [143]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Compendium of physical activities: an update of activity codes and MET intensities
AINSWORTH, B. E., HASKELL, W. L., WHITT, M. C., IRWIN, M. L., SWARTZ, A. M., STRATH, S. J., O???BRIEN, W. L., BASSETT, D. R., SCHMITZ, K. H., EMPLAINCOURT, P. O., et al. (2000) · Medicine & Science in Sports & Exercise · doi:10.1097/00005768-200009001-00009 · Cited by 8,497
Timmers, S., Konings, E., Bilet, L., Houtkooper, R. H., van de Weijer, T., Goossens, G. H., Hoeks, J., van der Krieken, S., Ryu, D., Kersten, S., et al. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2011.10.002 · Cited by 1,320
Brasnyó, P., Molnár, G. A., Mohás, M., Markó, L., Laczy, B., Cseh, J., Mikolás, E., Szijártó, I. A., Mérei, Á., Halmai, R., et al. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511000316 · Cited by 680
Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus
Bhatt, J. K., Thomas, S., & Nanjan, M. J. (2012) · Nutrition Research · doi:10.1016/j.nutres.2012.06.003 · Cited by 475
High-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Eslamparast, T., Poustchi, H., Zamani, F., Sharafkhah, M., Malekzadeh, R., & Hekmatdoost, A. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.068890 · Cited by 412
Rivera, L., Morón, R., Zarzuelo, A., & Galisteo, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.11.027 · Cited by 391
Yoshino, J., Conte, C., Fontana, L., Mittendorfer, B., Imai, S., Schechtman, K. B., Gu, C. C., Kunz, I., Fanelli, F. R., Patterson, B. W., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.09.015 · Cited by 389
GI Epidemiology: nonalcoholic fatty liver disease
Angulo, P. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03246.x · Cited by 370
Qiao, Y., Sun, J., Xia, S., Tang, X., Shi, Y., & Le, G. (2014) · Food & Function · doi:10.1039/c3fo60630a · Cited by 367
Faghihzadeh, F., Adibi, P., Rafiei, R., & Hekmatdoost, A. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.09.005 · Cited by 349
Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease
Chachay, V., Macdonald, G. A., Martin, J. H., Whitehead, J. P., O'Moore‐Sullivan, T. M., Lee, P., Franklin, M. E., Klein, K., Taylor, P. J., Ferguson, M. L., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.024 · Cited by 296
Non-alcoholic fatty liver disease pathogenesis: The present and the future
Petta, S., Muratore, C., & Craxı̀, A. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.01.004 · Cited by 287
Pilot study of resveratrol in older adults with impaired glucose tolerance
Crandall, J. P., Oram, V., Trandafirescu, G., Reid, M., Kishore, P., Hawkins, M., Cohen, H. W., & Barzilai, N. (2012) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glr235 · Cited by 281
Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase
SHANG, J., CHEN, L.-L., XIAO, F.-X., SUN, H., DING, H.-C., & XIAO, H. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00807.x · Cited by 274
Thirunavukkarasu, M., Penumathsa, S. V., Koneru, S., Juhász, B., Zhan, L., Otani, H., Bagchi, D., Das, D. K., & Maulik, N. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.05.004 · Cited by 271
Resveratrol inhibits nonalcoholic fatty liver disease in rats
Bujanda, L., Hijona, E., Larzábal, M., Beraza, M., Aldazábal, P., García‐Urkía, N., Sarasqueta, C., Cosme, Á., Irastorza, B., González, A., et al. (2008) · BMC Gastroenterology · doi:10.1186/1471-230x-8-40 · Cited by 226
Yilmaz, Y. N. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12046 · Cited by 217
Bo, S., Ciccone, G., Castiglione, A., Gambino, R., Michieli, F. D., Villois, P., Durazzo, M., Cavallo‐Perin, P., & Cassader, M. (2013) · Current Medicinal Chemistry · doi:10.2174/0929867311320100009 · Cited by 209
Askari, F., Rashidkhani, B., & Hekmatdoost, A. (2013) · Nutrition Research · doi:10.1016/j.nutres.2013.11.005 · Cited by 167
Gómez‐Zorita, S., Fernández‐Quintela, A., Macarulla, M. T., Aguirre, L., Hijona, E., Bujanda, L., Milagro, F. I., Martínez, J. A., & Portillo, M. P. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511002753 · Cited by 163
Resveratrol ameliorates hepatic metaflammation and inhibits NLRP3 inflammasome activation
Yang, S. J., & Lim, Y. (2014) · Metabolism · doi:10.1016/j.metabol.2014.02.003 · Cited by 141
Li, L., Jie, H., Li, Z., Zhang, Y., Peng, H., Li, K., & Weng, X. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.08.036 · Cited by 136
Eslamparast, T., Zamani, F., Hekmatdoost, A., Sharafkhah, M., Eghtesad, S., Malekzadeh, R., & Poustchi, H. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514000919 · Cited by 130
Cho, S.-J., Jung, U. J., & Choi, M. (2012) · British Journal Of Nutrition · doi:10.1017/s0007114512000347 · Cited by 130
Effect of 6-month nutritional intervention on non-alcoholic fatty liver disease
Elias, M. C., Parise, E. R., de Carvalho, L., Szejnfeld, D., & Netto, J. P. (2009) · Nutrition · doi:10.1016/j.nut.2009.09.001 · Cited by 98
How Much Weight Loss is Effective on Nonalcoholic Fatty Liver Disease?
Ghaemi, A., Taleban, F. A., Hekmatdoost, A., Rafiei, A., Hosseini, V., Amiri, Z., Homayounfar, R., & Fakheri, H. T. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.15227 · Cited by 80
Nonalcoholic Fatty Liver Disease
Law, K., & Brunt, E. M. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.07.006 · Cited by 77
Xin, P., Han, H., Gao, D., Cui, W., Yang, X., Ying, C., Sun, X., & Hao, L. (2012) · Food and Chemical Toxicology · doi:10.1016/j.fct.2012.10.026 · Cited by 71
Labbé, A., Garand, C., Cogger, V. C., Paquet, É. R., Desbiens, M., Couteur, D. G. L., & Lebel, M. (2010) · The Journals of Gerontology Series A · doi:10.1093/gerona/glq184 · Cited by 71
Burgess, T. A. (2011) · Archives of Surgery · doi:10.1001/archsurg.2011.100 · Cited by 65
Choi, Y., Suh, H.-R., Yoon, Y., Lee, K. J., Kim, D. G., Kim, S., & Lee, B. (2014) · Archives of Pharmacal Research · doi:10.1007/s12272-014-0347-z · Cited by 47
Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy
Malekzadeh, R., & Poustchi, H. (2011) · Hepatitis Monthly · Cited by 31
Malekzadeh, R., & Poustchi, H. (2011) · PubMed · Cited by 31
Furimsky, A. M., Green, C. E., Sharp, L. E. H., Catz, P., Adjei, A. A., Parman, T., Kapetanović, I. M., Weinshilboum, R. M., & Iyer, L. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.016725 · Cited by 29
Cited by
Sorted by citations
ESPEN guideline on clinical nutrition in liver disease
Plauth, M., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Bischoff, S. C. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.12.022 · Cited by 674
“One 500 mg capsule of resveratrol together with lifestyle intervention was more effective than lifestyle intervention alone in overweight patients regarding improvement in ALT, inflammatory cytokines and hepatic steatosis; this randomized controlled trial obviously was published in duplicate [325,326].”
MethodAntioxidant effects of resveratrol in the cardiovascular system
Xia, N., Daiber, A., Förstermann, U., & Li, H. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13492 · Cited by 583
Health benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
“A decrease in the levels of ALT and hepatic steatosis were also observed in other studies.(130) Conversely, in an 8 week trial, none of the characteristic features of NAFLD were significantly improved even at a resveratrol dose as high as 3000mg.”
Resveratrol and Cardiovascular Diseases
Bonnefont‐Rousselot, D. (2016) · Nutrients · doi:10.3390/nu8050250 · Cited by 463
ESPEN practical guideline: clinical nutrition in liver disease
Bischoff, S. C., Bernal, W., Dasarathy, S., Merli, M., Plank, L. D., Schütz, T., & Plauth, M. (2020) · Clinical Nutrition · doi:10.1016/j.clnu.2020.09.001 · Cited by 383
“One 500 mg capsule of resveratrol together with lifestyle intervention was more effective than lifestyle intervention alone in overweight patients regarding improvement in ALT, inflammatory cytokines and hepatic steatosis [166,167].”
Method
Metadata
- Authors
- Faghihzadeh, F., Adibi, P., & Hekmatdoost, A.
- Affiliations
- National Nutrition and Food Technology Research Institute (IR)
- Corresponding author
- Hekmatdoost, Azita
- ORCID
- Hekmatdoost, Azita
- Venue
- British Journal Of Nutrition
- Publisher
- Cambridge University Press (CUP)
- Published
- 2015-08-03
- Volume
- 114
- Issue
- 5
- Pages
- 796-803
- ISSN
- 0007-1145 (ISSN-L)
- 1475-2662
- OpenAlex
- W2246929884
- Cited by
- 188
- References
- 35
- Citations by year
- 2026: 9 · 2025: 9 · 2024: 17 · 2023: 13 · 2022: 28 · 2021: 18 · 2020: 17 · 2019: 15 · 2018: 20 · 2017: 12 · 2016: 25 · 2015: 2
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal Of Nutrition (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Science Foundation
- Iran National Science Foundation
- National Nutrition and Food Technology Research Institute
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Keywords
- resveratrol, non-alcoholic fatty liver disease, cardiovascular risk factors, insulin resistance, alanine aminotransferase, hepatic steatosis, lipid profile, blood pressure, hypertriglyceridemia, dietary supplementation
- MeSH terms
- Resveratrol, Adult, Alanine Transaminase, Anti-Inflammatory Agents, Antioxidants, Blood Pressure, Cardiovascular Diseases, Double-Blind Method, Fatty Liver, Female, Humans, Insulin Resistance, Liver, Male, Phytotherapy, Middle Aged, Plant Extracts, Risk Factors, Stilbenes, Triglycerides, Biomarkers, Dietary Supplements, Lipid Metabolism, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
